Plasma exosomal caveolin-1 predicts Poor Prognosis in Ovarian Cancer

Abstract

Objective: In this study, we aimed to evaluate the levels of plasma exosomal caveolin-1(CAV1) and determine its prognostic value in ovarian cancer patients. Patients and Methods: Exosome-rich fractions were isolated from the plasma of 155 patients with ovarian cancer. TEM, NTA and western blot analysis were used to confirm the exosome integrity and purification. Results: Compared with healthy controls, plasma exosomal CAV1 levels in ovarian cancer patient were significantly down-regulated (P < 0.001). The low plasma levels of exosomal CAV1 in ovarian cancer patient plasma were related to FIGO stages, grades and lymph node metastasis (all P < 0.01). Among all ovarian cancer patients, DFS was worse in patients who had low plasma exosomal CAV1 levels compared with that in patients with high plasma exosomal CAV1 levels (P < 0.001). The OS of patients with low plasma exosomal CAV1 levels was shorter than that in patients with high plasma exosomal CAV1 levels (P < 0.001). The AUROC of plasma exosomal CAV1 was 0.76 (95% CI: 0.68-0.82) for DFS prediction in ovarian cancer patients, with a sensitivity 52.9 (95% CI: 42.8-62.9) and a specificity 88.7 (95% CI: 77.0-95.7). For OS prediction in ovarian cancer patients, the AUROC of plasma exosomal CAV1 was 0.78 (95% CI: 0.70-0.84), with a sensitivity 65.1 (95% CI: 49.1-79.0) and a specificity 81.2 (95% CI: 72.8-88.0). Conclusions: Low exosomal CAV1 levels were closely related to the FIGO stages I/II, low grade, lymph node metastasis and prognosis of ovarian cancer patients. Plasma exosomal CAV1 may be a potential biomarker for the prognosis in ovarian cancer patients.

Increased Plasmatic Levels of Exosomes Are Significantly Related to Relapse Rate in Patients with Oral Squamous Cell Carcinoma: A Cohort Study

“…This investigation has revealed a noteworthy association between pre-and postsurgical exosome levels and a statistically significant risk of disease recurrence, as previously reported [62][63][64][65]. Interestingly, a study comparing disease-free intervals in ovarian cancer patients reported a negative correlation with cav-1 exosomes, revealing a paradoxical relationship between exosome expression and cancer prognosis [66]. Jiang et al have recently confirmed these phenomena in liver tumors [67].…”

Molecular pathogenesis, mechanism and therapy of Cav1 in prostate cancer

“…Cav1 is present in different cell types, tumor stages and locations, and its biological effects may vary. Cav1 may be closely related to the progression of some malignant tumors, such as bladder cancer [ 52 , 53 ], ovarian cancer [ 54 , 55 ], lung cancer [ 56 , 57 ], among which its role in PCa [ 58 , 59 ] being the most extensively explored. Cav1 expression is different in different types and stages of PCa, which affects the progression of PCa.…”

The Immunomodulation Potential of Exosomes in Tumor Microenvironment

“…More than 150 unique exosomal miRNAs are identified in cancer patients, and hsa-miR-320d, hsa-miR-320c, and hsa-miR-320b may be potential biomarkers to predict treatment efficacy of PD-1/PD-L1 immunotherapy in lung cancers [ 108 ]. The levels of plasma exosomal caveolin-1 are found to be downregulated in ovarian cancer, and they are positively associated with prognosis and overall survival as a biomarker [ 109 ]. Similarly, plasma-derived exosomal miR-4732-5p is also highly expressed in epithelial ovarian cancer patients and could be used to monitor cancer progression [ 110 ].…”